Summary
There are four common indications seen in Q2 Big/Suspected Movers
NASH/Liver disease, kidney disease, eye disease, and mental health
See below for the 21 assets in these four indications and which we are most excited for!
Sign up to become a BPIQ subscriber and see all Big events coming in Q2 2023. Learn more here.
The four most common indications seen in the Q2 2023 Movers list are NASH/Liver disease, kidney disease, eye disease, and mental health. These indications may be of special interest to investors because of their commonality in our Big Movers and Suspected Movers lists!
NASH & Liver disease
VKTX - VK2809 for NASH (Ph2 data)
NGM - Aldafermin for NASH w/ liver fibrosis (Ph2b data)
ICPT - Ocaliva for liver fibrosis due to NASH (AdComm)
AKRO - Efruxifermin for pre-cirrhotic NASH (Ph2b data)
VIR - VIR-2218 for hepatitis B virus (Ph2 data)
GNFT - Elafibranor for Primary biliary cholangitis (Ph3 data)
HEPA - HEPA-CRV431-210 for NASH (Ph2 data)
Eye disease
EYEN - MicroStat for Eye disease (PDUFA approval)
ALDX - ADX-2191 for Retinitis pigmentosa (PDUFA approval)
ANNX - ANX007 for Geographic atrophy (Ph2 data)
PTN - PL9643 for Dry eye disease (Ph3 data)
VRDN - VRDN-001 for Chronic thyroid eye disease (Ph2 data)
Kidney disease
TVTX - Sparsentan for Focal segmental glomerulosclerosis (Ph3 data)
GLPG - GLPG2737 for autosomal dominant polycystic kidney disease (Ph2 data)
ELOX - ELX-02 for alport syndrome (Ph2 data)
Big run-up for ELOX! up 190% in 2023, especially since beginning of April (See Fig 1)
FIG. 1 - ELOX run-up through 2023
Mental health
LPCN - LPCN1154 for PPD (Ph2 data)
SEEL SLS-002 for ASIB-MDD (Ph2 data)
BTAI - BXCL501 for Acute agitation in schizophrenia (Ph3 data)
AMRX - IPX203 for Parkinson's disease (PDUFA approval)
ALZN - AL001 for Alzheimer's disease (Ph2 data)
The Big Movers / those we are most excited for in these indications...
LPCN (Q2) - Ph2 data (Big Mover)
Run up - no run up this year. Down 35% in 2023
SEEL (Q2) - Ph2 data (Big Mover)
Run up - no run up this year. Only down 1% this year
EYEN (May 8) - PDUFA (Big Mover)
Run up - run up in 2023, up over 200% in 2023! (See Fig 2)
NASH assets are huge this quarter!
AKRO (Q2) - Ph2b data (Suspected Mover)
Run up - run up since beginning of April, +11% in last month
ICPT (May 19) - PDUFA AdComm (Suspected Mover)
Run up - run up from Jan to beginning of March 2023, then up again +26% since beginning of April
VKTX (Q2) - Ph2 data (Suspected Mover)
Run up - up over 150% this year! Especially with a big jump since the end of March (See Fig 3)
FIG. 2 - EYEN run-up through 2023
FIG. 3 - VKTX run-up through 2023
In early April we published our updated Movers list that includes events through the first half of the year! See this post for all upcoming Movers in Q2.
Become a BPIQ subscriber to see our full list of over 50 events!
BiopharmaIQ is proud to be the Big-Mover™ catalyst company. With all these exciting readouts on our Q2 2023 lists, you are likely to find a few that pique your interest. See our Full Q2 2023 Big Movers forum post HERE.
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
This article will likely be updated from time to time
Article History:
4/28/23 Initial publication of Q2 Big Indication list
This article is NOT investment, tax, or legal advice. Please use this as a starting point for your detailed diligence and consult professional advisers before making investment decisions.